BIA-ALCL (Breast Implant-Associated Anaplastic Large Cell Lymphoma) is a very rare form of T-cell lymphoma associated with breast implants. Since first identified in 2011, cumulative cases worldwide exceed 1,300. This guide reflects current FDA 2024 and WHO 2025 data, and explains clearly which implants are safe and which are higher-risk.

Critical facts at a glance

Topic	Current Knowledge
Incidence	1 in 30,000 to 1 in 100,000 per implant (varies by texture)
Typical diagnosis time	7-10 years after surgery (mean 8.5 years)
Risk factor	Macro-textured implant surface (especially Allergan BIOCELL)
Lower risk	Smooth, micro-textured, nano-surfaced implants
Most common first sign	Unilateral late-onset seroma (fluid accumulation)
5-year survival	89-93% (with early diagnosis + complete capsulectomy)
Treatment	Surgical removal of implant + entire capsule (en-bloc capsulectomy); chemotherapy in advanced cases

Which implants are higher-risk?

Almost all BIA-ALCL cases (>95%) have occurred with macro-textured implants. The rougher the surface, the higher the risk.

Surface Type	Roughness (Sa, μm)	BIA-ALCL Risk	Example Brands	Status
Smooth	<10	Very low (near zero)	Mentor MemoryGel Smooth, Sebbin Smooth	Safe
Nano-surface	10-50	Very low	Motiva SmoothSilk	Safe
Micro-textured	50-100	Low (1/100,000+)	Mentor Siltex, Sebbin Microtex	Generally considered safe
Macro-textured	>100	Higher (1/3,000-1/30,000)	Allergan BIOCELL, Eurosilicone Cristalline	FDA-recalled in 2019

Our clinic policy: only smooth or nano-surface implants (Motiva SmoothSilk, Mentor MemoryGel Smooth) and low-micro-texture (Sebbin) are used. No macro-textured model is used. This places patient safety ahead of brand or pricing convenience.

The FDA Allergan BIOCELL recall (July 2019)

In July 2019, the FDA issued a worldwide "Class 1 Recall" for Allergan's BIOCELL macro-textured implants and tissue expanders. This is the most serious recall category. At that time, approximately 85% of all BIA-ALCL cases were associated with BIOCELL implants.

BIOCELL implants today:

No longer sold (withdrawn by manufacturer)
For previously placed BIOCELLs: If asymptomatic, FDA does not recommend prophylactic removal. Routine surveillance suffices.
If symptomatic: Prompt evaluation. Unilateral late seroma → BIA-ALCL must be ruled out.

If you had surgery before 2019 and don't know which implant was placed, request your implant passport from your previous surgeon. This document records brand, model, serial number, lot number.

Symptoms — when to be concerned?

The most common first symptom of BIA-ALCL is late-onset unilateral seroma — that is, fluid accumulating in one breast 7-10 years after the implant surgery, causing sudden swelling.

Classic findings

Pronounced unilateral swelling: Enough to create asymmetry (becomes obvious within 1-2 weeks)
Pain: Mild-moderate, persistent
Skin changes: Sometimes redness or bruising
Mass palpable around capsule: Less common
Palpable lymph node under skin: Axillary (armpit) region

Important distinction: Early seroma (first 6 months) is usually normal and resorbs spontaneously. Late seroma (1+ year) is considered pathologic and must be aspirated under ultrasound and sent for pathology.

Diagnostic process — step by step

Clinical examination: Unilateral swelling, pain, asymmetry.
Breast US / MRI: Detection of fluid around capsule, mass screening.
Ultrasound-guided fluid aspiration: Sterile technique. At least 50 ml fluid drawn.
Cytology + immunohistochemistry: Staining for CD30+ and ALK-negative T-cells. Read by a pathologist.
PET-CT: To assess whether disease has spread.
Oncology / haematology consultation: Treatment planning.

Treatment — curative if caught early

BIA-ALCL differs greatly from other aggressive lymphomas: in localised, contained disease, complete surgical removal of implant + capsule (en-bloc total capsulectomy) can be sufficient on its own. Chemotherapy is not always required.

Stage	Finding	Treatment	5-year Survival
IA (fluid-confined)	Lymphoma in pericapsular fluid only	En-bloc capsulectomy + implant removal	95-100%
IB-II (capsule wall invasion)	Penetrated capsule wall	Surgery + adjuvant chemotherapy (CHOP regimen)	~90%
III-IV (disseminated)	Lymph node, distant organ	Chemotherapy + sometimes bone marrow transplant	65-75%

Recommendations for current implant carriers

Prophylactic removal is not recommended in asymptomatic patients. FDA, ASPS and ISAPS agree.
Annual self-examination: Be aware of unilateral changes (growth, pain, asymmetry).
FDA recommendation: For silicone implant carriers, follow-up MRI every 2-3 years starting at year 5-6.
Suspected late seroma: Contact your surgeon promptly. Rapid rule-out is performed.
Keep your implant passport: Brand, model, lot number may matter later.

BIA-ALCL vs BII (Breast Implant Illness)

These two conditions should not be confused:

Feature	BIA-ALCL	BII
Type	Oncologic (lymphoma)	Cluster of systemic complaints
Scientific evidence	Recognised by WHO and FDA	Causal relationship not yet demonstrated
Symptoms	Unilateral swelling, fluid accumulation	Fatigue, joint pain, brain fog (non-specific)
Diagnosis	Pathologic (CD30+ T-cells)	Clinical (no objective test)
Treatment	Surgery + chemo	Some symptom resolution after en-bloc capsulectomy in some patients

For detailed BII discussion: FAQ page — Implant Safety section.

Decision-making — BIA-ALCL informed

BIA-ALCL is a real risk, but with modern implant choices the risk drops practically below 1 in 100,000 — far lower than many everyday risks (e.g. car accident ~1 in 8,000). Informed decision:

Choose a surgeon who uses only smooth or nano-surface implants. The implant brand and model should be specified in writing pre-surgery.
Keep the implant passport. It comes with the warranty.
Do not skip routine MRI after year 5-6.
Be vigilant for late seroma. Unexplained unilateral swelling = surgeon immediately.

BIA-ALCL 2026 update: everything you need to know